Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix Efficacy and Safety in Healthy Japanese Females
NCT00316693Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2006
- Primary completion
- Feb 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Apr 2006; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00316693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316693.